Literature DB >> 7889395

Processing and major histocompatibility complex binding of the MTV7 superantigen.

G M Winslow1, P Marrack, J W Kappler.   

Abstract

Mouse mammary tumor viruses produce superantigens (vSAGs) which interact with class II major histocompatibility complex (MHC) proteins and stimulate T cells. vSAGs are synthesized as Type II membrane proteins, but at least one of these proteins (vSAG7) is found on the cell surface in a proteolytically processed form. Monoclonal antibodies (MAbs) were used to characterize vSAG7 and its binding to class II molecules. vSAG7 is synthesized in the endoplasmic reticulum (ER) as a 45 kd glycoprotein containing N-asparagine-linked oligomannosyl carbohydrates. vSAG7 transits the golgi complex, where it is modified by the addition of complex-type glycans and proteolysed at three positions. After proteolysis, the amino and carboxyl termini remain noncovalently associated. The ER, golgi, and surface forms of vSAG7 are stably bound to class II, but one of the proteolysed forms comprises the majority of the class II-bound material.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889395     DOI: 10.1016/1074-7613(94)90006-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  8 in total

1.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Shared promoter elements between a viral superantigen and the major histocompatibility complex class II-associated invariant chain.

Authors:  J Arroyo; E Winchester; B S McLellan; B T Huber
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

3.  In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.

Authors:  C Krummenacher; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat.

Authors:  S Wintersperger; B Salmons; T Miethke; V Erfle; H Wagner; W H Günzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Intercellular transfer of a soluble viral superantigen.

Authors:  M Reilly; D Mix; A A Reilly; X Y Ye; G M Winslow
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Mtv-1 superantigen trafficks independently of major histocompatibility complex class II directly to the B-cell surface by the exocytic pathway.

Authors:  M E Grigg; C W McMahon; S Morkowski; A Y Rudensky; A M Pullen
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Proteolytic processing activates a viral superantigen.

Authors:  D Mix; G M Winslow
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

8.  Proteolytic processing is required for viral superantigen activity.

Authors:  C G Park; M Y Jung; Y Choi; G M Winslow
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.